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Restoration of the tumor suppressor genes P53, Retinoblastoma, FHIT 
and FUS1 had only minimal effect on cell death, although the tumor 
suppressors are functional defective in >80 % of SCLC. 
Modulating the oncogene activity of Bcl-2 was attempted by introduc-
ing a truncated version of Bax, with increased apoptotic activity. Inhibi-
tion of Hsp70-mediated cancer survival was attempted by the introduc-
tion of Hsp40 J domain, a dominant negative gene inhibiting Hsp70 
activity. Although the gene products activated cellular death pathways 
in transfected cells, no signiﬁcant cell death was observed.
In contrast suicide gene strategies showed great potential for SCLC 
gene therapy. The suicide gene system herpes simplex virus thymidine 
kinase (HSVtk) with the prodrug ganciclovir (GCV) had already been 
tested and implemented at the laboratory showing >50 % cell death in 
vitro and tumor regression in vivo. HSVtk efﬁcacy was improved by 
the replacement of GCV with penciclovir (PCV), which demonstrated 
signiﬁcant less toxicity to untransfected cells. Another suicide gene 
system was implemented for testing: the yeast cytosine deaminase 
(YCD)gene either alone or fused with the yeast uracil phosphoribosyl-
transferase (YUPRT) gene and combined with the prodrug 5-FC. The 
YCD/YUPRT fusion gene showed superior efﬁcacy, mediating 90 % 
SCLC cell death. This dual suicide gene strategy targets in contrast to 
HSVtk/GCV or PCV, both DNA and RNA synthesis, also causing cell 
death to non-proliferating, dormant cancer cells. The strategy demon-
strated signiﬁcant bystander cytotoxicity due to the diffusion of toxic 
metabolites to nearby cancer cells, showing potential to overcome 
the low transfection efﬁciency currently characterizing in vivo gene 
therapy.
An update will be presented.
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Background: We assessed clinical dose-response curve (DRC) 
shape in extensive small cell lung cancer (SCLC) to gain insight into 
predominant resistance mechanism. We hypothesized DRC shape (log 
% cell survival vs linear dose) reﬂects resistance mechanisms, with a 
shoulder on the DRC indicating “active resistance” (excess resistance 
factor), decreased slope indicating “non-saturable passive resistance” 
(factor alteration/mutation) and a terminal plateau indicating “saturable 
passive resistance” (factor deﬁciency/saturation). We previously re-
ported that NSCLC DRCs ﬂatten at higher doses, suggesting saturable 
passive resistance.
Methods: Published SCLC clinical trials were reviewed. Response 
rates were converted into estimated mean tumor cell kill for each trial, 
assuming % tumor cell kill is proportional to % reduction in tumor 
volume. Complete remissions were assumed to represent 99% cell kill, 
partial remissions a 65-99% (mean 83%) cell kill, stable disease 13% 
cell kill and progression 0% cell kill. Mean % cell kill for a study was 
calculated based on % patients in each response category. Log mean % 
cell survival was plotted vs planned dose-intensity for each agent. Us-
ing data both weighted and unweighted for number of patients per trial, 
meta-regression analyses and nonlinear regression analyses were used 
to assess DRC shape.
Results: In metaregression analysis, efﬁcacy failed to vary signiﬁcantly 
with dose for all drugs assessed (cisplatin, carboplatin, etoposide, cy-
clophosphamide, ifosfamide, epirubicin and paclitaxel). For all agents, 
DRCs had reduced slopes or ﬂattened at higher doses.
Conclusions: While maximal mean % cell kill was greater with SCLC 
than in earlier NSCLC studies, outcomes were similar with respect to 
DRC ﬂattening at higher doses, suggesting that drug efﬁcacy is ulti-
mately limited by a deﬁciency or saturation of something required for 
drug effect. Lack of beneﬁt of high dose in most solid tumors suggests 
that this may also apply to most other epithelial malignancies. Based 
on DRC ﬂattening and other clinical and preclinical observations, we 
hypothesize: 1) With the ﬁrst chemotherapy cycle, quiescent cells are 
resistant and survive even high chemotherapy doses. 2) Cells surviving 
the ﬁrst cycle may upregulate expression of active resistance factors, 
permitting tumor regrowth between chemotherapy cycles or imme-
diately after chemotherapy. 3) Tumors unable to upregulate active resis-
tance sufﬁciently will down-regulate transporters, metabolism, etc, and 
will survive further chemotherapy through quiescence, with resumption 
of tumor growth delayed until some time beyond last chemotherapy 
administration. 4) Increasing drug doses may partially overcome active 
resistance, but tumors will then revert to saturable passive resistance. 
5) Active resistance factors play a role in differences in treatment ef-
ﬁcacy between patients and between studies, but the characteristic that 
is common to all is the ﬂattening of the DRC at high drug doses. 6) 
Major progress vs epithelial tumors will require enhanced targeting of 
quiescent cells. 7) The ability to cure some patients with limited SCLC 
with chemotherapy alone (and the enhanced cure rates when adjuvant 
therapy is used in localized NSCLC) suggests that the biology may 
possibly be different in localized vs advanced disease. Support: NCI 
Cancer Center Support Grant 5-P30 CA16672 to UTMDACC
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Introduction: Standard treatment for limited-stage small cell lung can-
cer is concurrent chemoradiation. The initial planning tumor volume 
(PTV) typically decreases in size during radiotherapy. For large tumors 
or in case of difﬁculty in meeting normal tissue constraints, our practice 
is to conduct a second simulation before the last third of the treatment 
course, usually before delivering 25 Gy, and irradiate a smaller boost 
volume for the remainder. We examined the effect of this practice on 
tissue sparing and local control.
Methods: Twenty-two patients with limited-stage small cell lung cancer 
were treated with deﬁnitive chemoradiation in 2006. Patients had three-
dimensional or intensity modulated radiation therapy developed on a 
Pinnacle treatment planning system using heterogeneity corrections and 
pre-determined dose-volume constraints. The volume of lung at 20 Gy 
(V20) was kept ≤35 Gy, the volume of heart at 40 Gy ≤40%, and the 
volume of esophagus at 50 Gy ≤50%; spinal cord maximum dose was 
45 Gy. For replanned patients, dose-volume histograms were plotted for 
the original plan versus the second plan and the composite plan.
Results: Of 22 patients, six underwent resimulation and replanning. 
The median decrease in PTV volume at the time of the replan was 56% 
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(range 28-87%). The median decrease in V20 in the replan was 8.4% 
(range 3.3-22.5%), resulting in a decrease of V20 of 1.7% (range 0.5-
5.1%) in the composite. For V5, V10, V30, and V45, replans showed 
a median improvement of 13.7% (range 0.7-43%), 11.0% (range 
0.2-33.4%), 9.0% (range 4.9-10.9%), and 4.6% (range 3.8-13.1%), 
respectively. Heart volumes at 40 Gy improved by 0.8% (range 0-
14.5%). The greatest improvements were seen in esophagus volumes at 
50 Gy, which improved by 28.6% (range 0-66.8%), for an improvement 
of 23% in the composite plan. In patients receiving higher doses, V60 
and V65 improved by 4.0% (range 0-11.2%) and 0.2% (range 0-5.9%), 
respectively. At a median follow-up of 4.2 months, no patient had local 
or distant relapse.
Conclusions: Small cell lung cancer planning target volumes can 
decrease by half during a deﬁnitive chemoradiation treatment course. 
Resimulation and replanning reduces the volumes of normal lung 
treated for the last third of the course. Volumes of heart and esophagus 
at tolerance doses are also reduced. At early follow-up, mid-course 
resimulation does not compromise local control.
Figure 1: Dose-volume histogram for original radiotherapy plan (thick line) 
versus second plan (thin line) and composite plan incorporating resimulation 
volumes (dashed).
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Introduction: UCN-01 inhibits several serine-threonine kinases, 
causes arrest of cell cycle progression at G1/S phase, induces apoptosis 
of SCLC cell lines, and has shown synergistic activity with topotecan. 
Phase II doses of UCN-01 in combination with topotecan had been 
previously determined in another PMH-C study. The objective of the 
current study was to determine the antitumor activity of UCN-01and 
topotecan in pts with SCLC relapsing more than 3 months after the 
completion of ﬁrst-line platinum-based combination chemotherapy. 
Methods: Eligibility criteria included: age > 18, ECOG PS 0-2, 1 prior 
platinum-based chemotherapy regimen completed at least 3 months 
prior to enrollment. Pts with coronary artery disease, a requirement for 
insulin, or prior topoisomerase I inhibitor were excluded. Pts received 
UCN-01 70 mg/m2 (cycle 1) or 35 mg/m2 (cycles 2+) IV day 1 plus 
topotecan 1 mg/m2 IV days 1-5 q21 days. Response was assessed by 
RECIST every 2 cycles. A two-stage design was used; if at least 4 
responses were seen in the ﬁrst 17 evaluable pts; the cohort would be 
expanded. 
Results: 17 pts have been enrolled over 24 months, 1 never received 
treatment due to CNS disease. Of 16 eligible patients, 9 are female, 
15 PS 0/1, median age 57 [range 50-73], median time from ﬁrst line 
therapy = 6.5months). Median number of cycles = 4 (range 1 -6). Com-
mon grade 3/4 toxicities: leukopenia (73% of patients) neutropenia (67 
%), lymphopenia (47%), thrombocytopenia (33 %), hyponatremia (27 
%), fatigue (27 %), pneumonia (20%). There were 3 serious adverse 
events: grade 3 pneumonia (1) and febrile neutropenia (2). Antitumor 
activity: PR = 1; SD = 7; Progression = 7; too early=1. 
Conclusions: This combination appears well-tolerated, but does not 
appear more active than standard single-agent topotecan. The study 
does not fulﬁll criteria to proceed to stage 2. 
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Background: The treatment of patients with limited disease small cell 
lung cancer (LD-SCLC) consists of concurrent chemo-radiotherapy, 
at the expense of dose-limiting acute esophagitis and lung damage. A 
straightforward strategy to reduce toxicity is to diminish the radiation 
ﬁelds. In NSCLC, radiation ﬁelds could be safely reduced by selective 
nodal irradiation, based on CT, and even further based on FDG-PET 
scans. However, in a phase II study in LD-SCLC, we observed 11% of 
isolated nodal failures. As literature suggests that also in SCLC, PET 
scan is more accurate than CT in identifying regional lymph nodes, 
we hypothesized that in patients with LD-SCLC, there would be less 
geographical miss by using PET scans compared to CT and hence there 
would be changes in the radiation exposure of normal tissues. 
Methods: Twenty-one consecutive patients with LD-SCLC were stud-
ied. For each patient, two three-dimensional conformal treatment plans 
were made where only the pathological lymph nodes were included in 
the GTV, either based on CT or on PET scan, both to a dose of 45 Gy 
in 30 fractions (1,5 Gy BID). The dosimetric factors associated with 
lung (MLD: Mean Lung Dose; V20) and esophageal toxicity (Dmax: 
maximal esophageal dose; MED: Mean Esophageal Dose) were ana-
lyzed and compared. All values are expressed as mean±SD. Wilcoxon’s 
signed rank test was used to compare differences.
